Results 81 to 90 of about 5,438,535 (291)

Structural studies and functional engineering of NanX: an anhydro‐sialic acid transporter from Escherichia coli

open access: yesFEBS Open Bio, EarlyView.
Biophysical characterisation shows that NanX, a membrane transport protein from the major facilitator superfamily (MFS), forms both monomers and dimers after purification. AlphaFold modelling and substrate docking provide information on residues likely involved in substrate recognition for NanX and another MFS member, NanT.
Michael C. Newton‐Vesty   +13 more
wiley   +1 more source

Purification and preparation of Marchantia polymorpha Auxin Response Factor 2 for phase separation studies

open access: yesFEBS Open Bio, EarlyView.
We describe detailed protocols for the purification and preparation of Marchantia polymorpha Auxin Response Factor 2 (MpARF2). This protein is fused to an MBP solubility tag and an mNG fluorescent tag and is purified from Escherichia coli. The presented procedures make it possible to study MpARF2 assemblies, which could arise from phase separation ...
Bas Janssen   +5 more
wiley   +1 more source

Size‐exclusion chromatographic NMR of polymer mixtures

open access: yes, 2014
The use of chromatographic stationary phases or solvent modifiers to modulate diffusion properties in NMR experiments is now well established. Their use can be to improve resolution in the diffusion domain or to provide an insight into analyte–modifier ...
Iain J. Day   +5 more
core   +1 more source

Structural and biochemical insights into the thermostable esterase Ta0887 from Thermoplasma acidophilum

open access: yesFEBS Open Bio, EarlyView.
In this study, a novel esterase from the thermoacidophilic archaeon Thermoplasma acidophilum was biochemically and structurally characterized. Our results demonstrate that Ta0887 is a highly thermostable esterase that preferentially hydrolyzes p‐nitrophenyl hexanoate and possesses an α‐helical cap domain that likely contributes to its substrate ...
Alejandro Delgado‐Rey   +4 more
wiley   +1 more source

Fast size-exclusion chromatography at high temperature

open access: yes, 2014
We report on the size-exclusion chromatography (SEC) operated at high column temperature to reduce the analysis time. The column temperature was raised beyond the normal boiling point of the eluent and a sufficient column backpressure was applied to ...
Cho, HS   +9 more
core   +1 more source

A minimal cellulosome‐like system in Cellulosilyticum lentocellum

open access: yesFEBS Open Bio, EarlyView.
Cellulose‐degrading bacteria typically use cellulosomes, large multi‐enzyme complexes on a scaffold protein. In Cellulosilyticum lentocellum, we characterise a far smaller arrangement, a single scaffold bound to one cellulase through a single cohesin‐dockerin interaction.
John Allan   +2 more
wiley   +1 more source

Inverse Size-Exclusion Chromatography

open access: yes, 2017
The most preferred method to separate sample molecules based on their size relative to the pore size is size exclusion chromatography (SEC) (also referred to as gelpermeation, gel-filtration, molecular sieve, or simply gel chromatography) because ...
Bacskay, Ivett   +2 more
core   +1 more source

Multidimensional separation platform based on column swich recycling size exclusion chromatography for high efficiency analysis of proteins

open access: yes, 2008
Multidimensional separation platform based on column swich recycling size exclusion chromatography for high efficiency analysis of ...
梁振, 袁辉明, 张玉奎, 张丽华
core  

Size exclusion chromatography of HtrA3 protein variants.

open access: yes, 2015
Calculated molecular mass is an average of at least three independent experiments. ΔN-HtrA3 to β-casein molar ratio was calculated for ΔN-HtrA3 trimers.
Miroslaw Jarzab (760768)   +9 more
core   +1 more source

Plasma EV Proteomics Identifies ECM Remodeling and Inflammatory Proteins LUM and C7 as Candidate Biomarkers in FSHD

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Facioscapulohumeral muscular dystrophy (FSHD) is one of the most debilitating and common muscular dystrophies. Despite its severity, no approved therapy exists for FSHD patients. However, several therapeutic candidates are currently under development, and some have recently entered clinical trials, marking the need for reliable ...
Mustafa Bilal Bayazit   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy